← Leaderboards
Serge E Przedborski
Columbia University Health Sciences
$23,881,284
Attributed
$25,630,247
Total exposure
26
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,630,247 · 26
By mechanism
R01$12,054,475 · 6
R21$4,161,987 · 10
P50$4,140,980 · 4
UG3$2,658,871 · 1
P01$1,146,514 · 1
T35$559,370 · 1
Top collaborators
- Sachin Agarwal3 shared
- Jennifer Jaie Manly3 shared
- James Mccallum Noble3 shared
- Charles E Schroeder2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- James Eric Gouaux$46,215,893
- Wassim Elyaman$6,169,565
- Elisa E Konofagou$45,415,693
- Ralph Sacco$1,434,857
- Younan Xia$8,693,615
Others in their field
Top investigators on “Nerve Degeneration”
- Paul S. Aisen · Cognition Therapeutics, Inc.$113,855,136
- Reisa A. Sperling · Banner Health$83,196,776
- Randall J Bateman · Washington University$83,099,227
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$76,236,227
- Jose A Luchsinger · Columbia University Health Sciences$75,117,371
- Keith A. Johnson · Banner Health$70,466,464
Research focus
Nerve DegenerationBaseAmyotrophic Lateral SclerosisNeuronsMutantMotor NeuronsCellsMolecularGeneticInvestigationParalysedPathogenesisPhenotypeAdultIn VitroIn VivoMouse ModelPathway InteractionsParkinson DiseaseLaboratory MousePlayFutureSuperoxide Dismutase 1Response
Grant awards (87)
Brief Research In Aging and Interdisciplinary Neurosciences (BRAIN)$191,028
T35 · FY2025 · AG
Circuit-specific, chemogenetic neuromodulation in nonhuman primates.$1,108,413
UG3 · FY2024 · MH
Defining Immune Cell Heterogeneity in Human ALS and Mouse Model of the Disease$432,521
R01 · FY2024 · NS · contact PI
Brief Research In Aging and Interdisciplinary Neurosciences (BRAIN)$187,816
T35 · FY2024 · AG
A multiplexable in vivo perturbation toolkit to identify genes affecting neurodegeneration in a model of synucleinopathy$101,927
R21 · FY2024 · AG · contact PI
Circuit-specific, chemogenetic neuromodulation in nonhuman primates.$1,550,458
UG3 · FY2023 · MH
A multiplexable in vivo perturbation toolkit to identify genes affecting neurodegeneration in a model of synucleinopathy$452,375
R21 · FY2023 · AG · contact PI
Defining Immune Cell Heterogeneity in Human ALS and Mouse Model of the Disease$445,897
R01 · FY2023 · NS · contact PI
Brief Research In Aging and Interdisciplinary Neurosciences (BRAIN)$180,526
T35 · FY2023 · AG
Mechanisms of Axon Pathology in ALS$518,127
R01 · FY2022 · NS · contact PI
Defining immune cell heterogeneity in human ALS and mouse model of the disease$445,897
R01 · FY2022 · NS · contact PI
Mechanisms of Axon Pathology in ALS$522,649
R01 · FY2021 · NS · contact PI
Defining immune cell heterogeneity in human ALS and mouse model of the disease$450,923
R01 · FY2021 · NS · contact PI
Defining immune cell heterogeneity in human ALS and mouse model of the disease$641,443
R01 · FY2020 · NS · contact PI
Mechanisms of Axon Pathology in ALS$534,073
R01 · FY2020 · NS · contact PI
A transcriptomic atlas of immune cells in a model of synucleinopathy$324,000
R21 · FY2020 · AG · contact PI
Mechanisms of Axon Pathology in ALS$553,565
R01 · FY2019 · NS · contact PI
Focused ultrasound and synucleinopathy$445,500
R21 · FY2019 · NS · contact PI
Protein prenylation inhibition for the treatment of tauopathies$392,375
R01 · FY2019 · NS · contact PI
A transcriptomic atlas of immune cells in a model of synucleinopathy$121,500
R21 · FY2019 · AG · contact PI
Mechanisms of Axon Pathology in ALS$565,753
R01 · FY2018 · NS · contact PI
Non-cell Autonomous Role of Synuclein in Neurodegeneration$200,000
R21 · FY2018 · NS · contact PI
Role of MMP-9 in selective motor neuron degeneration in ALS$329,348
R01 · FY2017 · NS · contact PI
Non-cell Autonomous Role of Synuclein in Neurodegeneration$240,000
R21 · FY2017 · NS · contact PI
Enhancing Animal Care in a New High-Throughput Rodent Behavior Analysis Core Facility$500,000
G20 · FY2016 · OD · contact PI
Role of MMP-9 in selective motor neuron degeneration in ALS$329,469
R01 · FY2016 · NS · contact PI
The 4th World Parkinson Congress is a four-day scientific conference designed to bring the US and global Parkinson's community together for a variety of high level and novel educational symposia.$50,000
R13 · FY2016 · NS · contact PI
Role of MMP-9 in selective motor neuron degeneration in ALS$329,585
R01 · FY2015 · NS · contact PI
Signaling pathways of necroptosis$200,000
R21 · FY2015 · NS · contact PI
Role of MMP-9 in selective motor neuron degeneration in ALS$326,403
R01 · FY2014 · NS · contact PI
Signaling pathways of necroptosis$240,000
R21 · FY2014 · NS · contact PI
Evaluating HMG-CoA reductase as a therapeutic target in ALS$198,000
R21 · FY2014 · NS · contact PI
PATIENT FIBROBLAST RESEARCH CORE$166,070
P50 · FY2013 · NS · contact PI
Neuroscience Core$77,302
P50 · FY2013 · NS · contact PI
Proinflammatory enzymes in amytrophic lateral sclerosis$417,893
R01 · FY2012 · NS · contact PI
Pre-clinical testing of necrostatin as a potential small molecule for the treatme$200,000
R21 · FY2012 · NS · contact PI
PATIENT FIBROBLAST RESEARCH CORE$183,564
P50 · FY2012 · NS · contact PI
Neuroscience Core$85,444
P50 · FY2012 · NS · contact PI
Proinflammatory enzymes in amytrophic lateral sclerosis$466,118
R01 · FY2011 · NS · contact PI
Pre-clinical testing of necrostatin as a potential small molecule for the treatme$240,750
R21 · FY2011 · NS · contact PI
PATIENT FIBROBLAST RESEARCH CORE$172,095
P50 · FY2011 · NS · contact PI
Neuroscience Core$80,107
P50 · FY2011 · NS · contact PI
Proinflammatory enzymes in amytrophic lateral sclerosis$501,392
R01 · FY2010 · NS · contact PI
A novel cell-based high-throughput assay for ALS$174,080
R21 · FY2010 · NS · contact PI
PATIENT FIBROBLAST RESEARCH CORE$167,082
P50 · FY2010 · NS · contact PI
Neuroscience Core$77,774
P50 · FY2010 · NS · contact PI
Proinflammatory enzymes in amytrophic lateral sclerosis$411,937
R01 · FY2009 · NS · contact PI
A novel cell-based high-throughput assay for ALS$210,394
R21 · FY2009 · NS · contact PI
Early motor neuron alteration in a non-cell autonomous ALS model$170,021
R21 · FY2009 · NS · contact PI
PATIENT FIBROBLAST RESEARCH CORE$166,092
P50 · FY2009 · NS · contact PI
Neuroscience Core$75,263
P50 · FY2009 · NS · contact PI
COX-2 in pathogenesis of Parkinsons Disease$322,384
P50 · FY2008 · NS · contact PI
Early motor neuron alteration in a non-cell autonomous ALS model$203,740
R21 · FY2008 · NS · contact PI
Neuroscience Core$159,192
P50 · FY2008 · NS · contact PI
COX-2 in pathogenesis of Parkinsons Disease$344,043
P50 · FY2007 · NS · contact PI
Mechanisms of Bax-mediated cell death in the MPTP model$310,055
R01 · FY2007 · AG · contact PI
Experimental Therapeutic Strategies for ALS$226,648
P01 · FY2007 · NS · contact PI
Neuroscience Core$169,879
P50 · FY2007 · NS · contact PI
COX-2 in pathogenesis of PD$331,180
P50 · FY2006 · NS · contact PI
Mechanisms of Bax-mediated cell death in the MPTP model$319,316
R01 · FY2006 · AG · contact PI
Experimental Therapeutic Strategies for ALS$236,493
P01 · FY2006 · NS · contact PI
Neuroscience Core$163,525
P50 · FY2006 · NS · contact PI
Mechanisms of Bax-mediated cell death in the MPTP model$327,000
R01 · FY2005 · AG
COX-2 in pathogenesis of PD$321,532
P50 · FY2005 · NS
Experimental Therapeutic Strategies for ALS$233,958
P01 · FY2005 · NS
Effect of enriched environment on ALS neurodegeneration$201,250
R21 · FY2005 · ES
Neuroscience Core$158,762
P50 · FY2005 · NS
COX-2 in pathogenesis of PD$312,167
P50 · FY2004 · NS
Proinflammatory enzymes in amyotrophic lateral sclerosis$299,297
R01 · FY2004 · NS
Effect of enriched environment on ALS neurodegeneration$238,450
R21 · FY2004 · ES
Experimental Therapeutic Strategies for ALS$227,867
P01 · FY2004 · NS
Neuroscience Core$155,973
P50 · FY2004 · NS
SYNUCLEIN AND NIGRAL DOPAMINERGIC NEURON DEGENERATION$315,993
R01 · FY2003 · NS
Proinflammatory enzymes in amyotrophic lateral sclerosis$300,106
R01 · FY2003 · NS
Experimental Therapeutic Strategies for ALS$221,548
P01 · FY2003 · NS
SYNUCLEIN AND NIGRAL DOPAMINERGIC NEURON DEGENERATION$325,669
R01 · FY2002 · NS
Proinflammatory enzymes in amyotrophic lateral sclerosis$300,889
R01 · FY2002 · NS
NITRIC OXIDE AND PROTEIN NITROTYROSINE IN THE MPTP MODEL$119,350
R29 · FY2002 · NS
Experimental models of nigral neuron degeneration$0
P50 · FY2002 · NS
Proinflammatory enzymes in amyotrophic lateral sclerosis$317,475
R01 · FY2001 · NS
SYNUCLEIN AND NIGRAL DOPAMINERGIC NEURON DEGENERATION$316,233
R01 · FY2001 · NS
NITRIC OXIDE AND PROTEIN NITROTYROSINE IN THE MPTP MODEL$119,350
R29 · FY2001 · NS
Experimental models of nigral neuron degeneration$0
P50 · FY2001 · NS
SYNUCLEIN AND NIGRAL DOPAMINERGIC NEURON DEGENERATION$307,074
R01 · FY2000 · NS
Experimental models of nigral neuron degeneration$225,775
P50 · FY2000 · NS
Experimental models of nigral neuron degeneration$225,775
P50 · FY2000 · NS
NITRIC OXIDE AND PROTEIN NITROTYROSINE IN THE MPTP MODEL$119,350
R29 · FY2000 · NS